Guggenheim Cuts Disney Price Target to $115 While Maintaining Buy Rating Guggenheim has lowered its price target for The Walt Disney Company (NYSE:DIS) from $140 to $115 while maintaining its 'buy' rating, signaling continued confidence in the stock despite near-term challenges. The revised target suggests a 15.77% potential upside from Disney’s current price of about $99 per share. Other firms, including Citigroup and TD Cowen, have also trimmed their price objectives in recent months, keeping a generally positive but cautious outlook on the entertainment giant. According to MarketBeat data, Disney currently carries an average analyst rating of 'Moderate Buy' and a consensus price target of $134.13. The company reported quarterly earnings of $1.63 per share, surpassing expectations by $0.06, on revenue of approximately $25.98 billion — up 5.2% year over year. With a market capitalization of roughly $176 billion, Disney maintains solid fundamentals with a net margin of 12.8% and return on equity of 8.9%. The firm’s debt-to-equity ratio remains low at 0.31, reflecting a stable financial position. Recent headlines show that Disney is entering a transition period under new CEO Josh D’Amaro, who aims to leverage Disney’s strengths in parks, streaming, and technology. The company also faces mixed sentiment from investors as it restructures divisions and settles a $50 million lawsuit related to livestream subscriptions. Analysts see both potential and risk as Disney seeks to revive growth, build investor confidence, and execute its 'One Disney' integration strategy that unites content, streaming, and park experiences under a coordinated commercial vision.

Guggenheim Cuts Disney Price Target to $115 While Maintaining Buy Rating

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#disney #stockmarket #analystratings

View full AI summary:

#AnalystRatings Zevra Therapeutics shares jumped over 17 percent in premarket trading Tuesday after reporting 2025 net income of $83 million on $106 million in revenue. Guggenheim raised its price target on the stock to $23 while maintaining a buy rating, citing 109 percent upsi ... Continue reading

#AnalystRatings CAVA Group reported double-digit revenue growth in Q4 FY25, driving shares up approximately 20-25% on February 25th. The Mediterranean restaurant chain delivered an earnings beat with surprise same-store sales growth attributed to menu pricing strategies. Managem ... Continue reading

#AnalystRatings Arcellx received downgrades from three major financial institutions on February 24, with UBS, Citigroup, and Leerink Partners all cutting their ratings from Buy or Outperform to Neutral or Market Perform. Both UBS and Leerink Partners project minimal upside of ap ... Continue reading

#AnalystRatings Tandem Diabetes Care reported fourth-quarter results that exceeded revenue and loss expectations, prompting multiple analyst upgrades. The company projects 10-11% pump shipment growth for 2026 as it transitions to its PayGo model. Following the earnings beat, ana ... Continue reading

#AnalystRatings Remitly Global stock jumped 20.8% in premarket trading after reporting a strong fourth quarter for 2025 and achieving its first full year of GAAP profitability. The digital remittances platform's performance prompted multiple analyst upgrades. Citizens raised its ... Continue reading

#AnalystRatings Nektar Therapeutics reported encouraging 36-week maintenance data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in atopic dermatitis. The drug demonstrated durable responses with 71% and 83% of patients maintaining EASI-75 responses on monthly and quart ... Continue reading

#AnalystRatings Bill Holdings shares jumped following Bloomberg reports that Hellman & Friedman is in talks to acquire the payments firm. The potential buyout news overshadowed a mixed day for the company, which saw multiple analyst downgrades after its Q2 2026 earnings call. Je ... Continue reading

#AnalystRatings Enphase Energy shares jumped 36.7% in premarket trading following fourth-quarter results that exceeded earnings and revenue estimates, along with an upbeat revenue forecast. The solar technology company's strong performance triggered multiple analyst upgrades and ... Continue reading

#AnalystRatings Korro Bio received three analyst upgrades to Buy or Overweight ratings on January 29th, with firms citing potential in the company's KRRO-121 candidate and UCD treatment programs. H.C. Wainwright projects 71% upside potential while Chardan Capital sees 28% upside ... Continue reading

#AnalystRatings ImmunityBio announced progress in regulatory discussions with the FDA regarding a potential resubmission path for Anktiva in BCG-unresponsive papillary bladder cancer. The FDA has requested additional information to support the supplemental biologics license appl ... Continue reading

#AnalystRatings Corvus Pharmaceuticals shares surged Tuesday following positive Phase 1 clinical trial data for soquelitinib, its atopic dermatitis treatment. The trial showed 75% of patients achieved EASI 75 improvement, 25% reached EASI 90, and 33% achieved IGA 0/1 scores. The ... Continue reading

#AnalystRatings Beta Bionics stock fell sharply, dropping over 15 percent in premarket trading after the company reported preliminary results showing new patient starts decelerated and missed key performance targets. An analyst flagged valuation concerns following the weaker-tha ... Continue reading

#AnalystRatings Century Therapeutics raised $135 million in an oversubscribed private placement to fund CNTY-813, its lead therapy for Type 1 Diabetes. New investor TCGX led the financing, joined by RA Capital, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Heal ... Continue reading

#AnalystRatings OneStream Inc. experienced widespread analyst downgrades on January 7th, with at least eight major financial institutions reducing their ratings. Wolfe Research, Morgan Stanley, Mizuho, BMO Capital, Loop Capital, and Needham all downgraded the stock to neutral-eq ... Continue reading

#AnalystRatings Erasca stock climbed to a 52-week high of $3.80 following Piper Sandler's initiation of coverage with an Overweight rating and 38% upside target. The analyst upgrade drove investor interest in the biotech company's shares.

#AnalystRatings Warby Parker shares jumped 27% following a Citigroup upgrade from Market Perform to Outperform and the announcement of an AI-powered smart glasses collaboration with Google launching in 2026. Citizens also upgraded the eyewear retailer to Outperform. The stock sa ... Continue reading

#AnalystRatings JPMorgan analyst Anupam Rama initiated coverage of Vor Biopharma with an Overweight rating and $43 price target, driving shares up 28 percent. Rama characterized telitacicept as a highly de-risked dual APRIL/BAFF therapy for myasthenia gravis and primary Sjogren' ... Continue reading

#AnalystRatings UiPath shares jumped 24 percent following third-quarter results and guidance that exceeded Wall Street expectations. The automation software company delivered solid execution across all metrics, with management signaling continued stability after completing its r ... Continue reading

#AnalystRatings Craig-Hallum downgraded PagerDuty to Hold from Buy, citing deflating growth expectations and seeing minimal upside. Morgan Stanley and RBC Capital lowered price targets to $16 and $17 respectively, though RBC maintained its Outperform rating. TD Cowen reduced its ... Continue reading

#AnalystRatings Nuvation Bio shares jumped 40 percent to a 52-week high of $5.57 after B Riley initiated coverage with a Buy rating, citing strong prospects for the company's Ibtrozi product launch.

#AnalystRatings Following PubMatic's Q3 2025 earnings call, Wolfe Research upgraded its price target to $12 while maintaining an Outperform rating, projecting 57% upside potential. The digital advertising technology company gained attention among trending stocks as analysts expr ... Continue reading

📊 This week’s Strong Buy stocks are in - analysts say these names could pop 🔎

Get the full list in our newsletter → investingintel.valuethemarkets.com/subscribe

#stocks #strongbuy #investing #analystratings #markets

--
Disclaimer: Info only. DYOR. valuethemarkets.com/disclaimer

Want stocks with serious analyst support? These picks all have Strong Buy ratings from S&P 500 giants to small-cap standouts.

Subscribe to read more 👉 investingintel.valuethemarkets.com/subscribe

#Investing #Stocks #StrongBuy #AnalystRatings #MarketIntel

Analyst shuffles chemical distribution names: Cuts Brenntag, upgrades IMCD, Azelis Investing.com -- Deutsche Bank has reshuffled its ratings across Europe’s chemical distribution sector, adopting a more selective stance as it downgraded Brenntag AG (ETR:BNRGn) while upgrading both IMCD (AS:IMCD) and Azelis (EBR:AZE). Brenntag was cut to Hold from Buy, with the price target slashed to €52 from €75. Analyst Tristan Lamotte said the downgrade reflects timing concerns, not a lack of potential. He pointed out that Brenntag’s higher cyclicality—particularly in its Essentials segment—makes it more exposed to pricing pressure and weaker end-markets. The company recently lowered its EBITA guidance to €950–1,050 million, down from €1.1–1.3 billion, amid signs of volume and margin stress. Deutsche’s 2025 EBITA forecast of €990 million sits roughly 7% below consensus. By contrast, IMCD was upgraded to Buy, with its target lifted to €136 from €126. Lamotte described IMCD as a high-quality name offering long-term growth at a reasonable valuation. “Over the past 16 years, IMCD has experienced only one year of EBITA decline, with current EBITA more than ten times greater than in 2009,” the note states. Furthermore, it delivered an average organic EBITA growth of over 10% from 2016 to 2024. The company’s return on capital employed has remained strong, supporting long-term total shareholder returns of around 15% annually over the past decade, surpassing even top performers like Givaudan and Air Liquide (OTC:AIQUY). Azelis also received a Buy rating, with Deutsche raising its target to €17 from €14. Lamotte highlighted the company’s potential as an under-recognized compounder with operational strength comparable to IMCD. While recent results were affected by cyclical timing and technical overhangs, including a large private equity stake and IPO timing, Azelis has delivered solid organic EBITA growth and margin performance. Lamotte noted that Azelis trades at a significant valuation discount—10.9x 2025 EV/EBITDA versus 14.5x for IMCD—despite comparable operational KPIs. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if BNRGn is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #ChemicalDistribution #AnalystRatings #Brenntag #IMCD #Azelis

Analyst resets Datadog stock price target after surprise addition to S&P 500 - Yahoo Finance Analyst resets Datadog stock price target after surprise addition to S&P 500  Yahoo Finance

Click Subscribe #Datadog #StockMarket #SP500 #FinanceNews #AnalystRatings

Starbucks service plan prompts surprising analyst stock-price-target revisions - TheStreet Starbucks service plan prompts surprising analyst stock-price-target revisions  TheStreet

Click Subscribe #Starbucks #StockMarket #AnalystRatings #BusinessNews #Finance

Analysts cut Deckers Outdoor rating following earnings release Investing.com -- Deckers Outdoor Corporation was hit with various analyst downgrades on Friday in reaction to its fiscal fourth-quarter earnings release, as concerns mounted over slowing growth at its key HOKA brand and macroeconomic headwinds. Telsey Advisory Group downgraded the stock to Market Perform from Outperform and slashed its price target in half from $240 to $120. Despite what Telsey called a “strong fourth quarter” with solid revenue growth and gross margin expansion, the firm cited “the deceleration of the HOKA and DTC businesses, margin pressures from channel mix shifts towards wholesale,” and tariff-related cost headwinds. KeyBanc downgraded Deckers to Sector Weight, pointing to “HOKA’s slowing trajectory, shift toward wholesale door growth, and potential demand erosion from price increases.” The firm added that while Deckers has executed well, “HOKA no longer feels as competitively positioned vs. other disruptive running brands that continue to outperform.” Evercore ISI joined the chorus with a downgrade to In-Line, warning that “the high growth story is behind us.” The firm believes Deckers is entering “a new phase of lower growth” as UGG and HOKA show signs of deceleration. It cited external headwinds like tariffs and softer consumer sentiment and said current valuations “properly reflect the emerging risk.” Analysts across the board pointed to HOKA’s slower customer acquisition in the U.S., increased promotions, and limited near-term catalysts as key concerns.

Click Subscribe #DeckersOutdoor #EarningsReport #StockMarket #InvestmentNews #AnalystRatings

PepsiCo Stock: Analyst Estimates & Ratings - Nasdaq PepsiCo Stock: Analyst Estimates & Ratings  Nasdaq

Click Subscribe #PepsiCo #StockMarket #Investing #Finance #AnalystRatings